Draft:Trimi Health
Submission declined on 11 May 2026 by BlueStaticHorse (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
Comment: In accordance with Wikipedia's Conflict of interest guideline, I disclose that I have a conflict of interest regarding the subject of this article. Csabbagh (talk) 17:15, 11 May 2026 (UTC)
| Type | Private |
|---|---|
| Industry | Telemedicine; Pharmaceutical compounding |
| Founded | May 2024 |
| Headquarters | , United States |
Area served | United States (all 50 states and Washington, D.C.) |
| Products | Compounded semaglutide; Compounded tirzepatide |
| Website | trytrimi |
Trimi Health is an American telehealth company that operates within a category of online providers that emerged in 2023–2024 dispensing compounded versions of GLP-1 receptor agonist medications during a federal shortage of the branded products.[1][2] The company is headquartered in New York City and was incorporated in May 2024.[3]
History
[edit]Trimi Health entered the United States telehealth market during a period of
significant disruption affecting weight-loss pharmacology. Semaglutide and
tirzepatide, the active ingredients in the brand-name medications Wegovy,
Ozempic, Mounjaro, and Zepbound, were both added to the U.S. Food and Drug Administration's national drug shortage list in 2022–2023, triggering a
regulatory window in which state-licensed 503A compounding pharmacies could prepare patient-specific versions of those drugs in response to
The shortage and resulting compounding window produced a substantial industry of
online telehealth platforms — including Hims & Hers Health, Ro, Henry Meds, Mochi
Health, and Trimi Health — that paired licensed prescribers with 503A pharmacy
partners. The FDA has repeatedly issued public warnings about consumer-safety risks
associated with this category, including dosing errors, salt-form contamination, and
online sellers operating outside legitimate medical practice.[5] The agency removed tirzepatide from the shortage list in late 2024,
narrowing the regulatory basis for compounding it, and has continued to issue
guidance affecting which 503A activities remain permitted.[1]
Operations
[edit]Clinical infrastructure
[edit]Clinical care on the platform is delivered by medical doctors and other licensed
prescribers contracted through Beluga Health, a multistate management services organization (MSO) that serves as a clinician network for telehealth platforms.
[2] Beluga Health holds LegitScript healthcare merchant
certification, is ISO/IEC 27001 and SOC 2 compliant, and licenses
prescribers in all 50 U.S. states and Washington, D.C.[2]
Provider profiles published on the Trimi Health website include Asad Niazi, M.D.,
M.P.H., listed as a prescribing clinician within the Beluga Health network.[6]Trimi Health itself holds active LegitScript Healthcare Merchant Certification,
a third-party compliance program used by major advertising and payment platforms to
verify that telehealth merchants meet applicable U.S. legal and regulatory
standards.[7]
Subsciption Model
[edit]Trimi Health operates on a recurring-subscription model with annual, semi-annual,
quarterly, and monthly billing options. The plans bundle medication, clinician
access, and shipping into a single monthly price.[2][8] Pricing varies by plan length and by which active ingredient is
prescribed; reviewers have noted the company's annual-billing price points are below
the typical range for comparable compounded-GLP-1 telehealth services.[2][9]
Reception and Criticism
[edit]Independent coverage of Trimi Health has been limited and primarily appears on
consumer lifestyle and health blogs rather than mainstream business or medical
press.
A 2026 long-form review by the consumer health publication MindBodyDad examined the
company's intake flow, clinician interaction, pricing, and pharmacy supply chain.
The reviewer described the model as a representative example of compounded-GLP-1
telehealth, identified the use of named 503A pharmacy partners as a transparency
factor, and concluded that the company was "a reliable option" within the category.
The same review also noted negative themes from third-party patient comments, citing
reports of "inconsistencies in some customer service experiences.
"[2] The reviewer characterized those reports as anecdotal.
The Cinnamon Hollow listed Trimi Health among "safe weight-loss prescription"
providers in a 2026 feature about online compounded GLP-1 options.[9] GenTwenty included the company in a 2026 roundup of online
health-management providers.[8]
The broader category in which Trimi Health operates has been the subject of
consumer-safety warnings from the FDA, including alerts about dosing errors with
compounded semaglutide and concerns about online sellers marketing compounded GLP-1
medications outside legitimate medical practice. Trimi Health has not been the
subject of such an FDA notice as of mid-2026.[5]
Regulatory Framework
[edit]The compounded medications dispensed through Trimi Health are not FDA-approved drug
products. They are prepared under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits state-licensed pharmacies to preparepatient-specific compounded medications in response to a valid prescription from a
licensed prescriber.[4] The active pharmaceutical ingredients —
semaglutide and tirzepatide — are themselves FDA-approved within the commercial
finished products marketed by Novo Nordisk and Eli Lilly and Company.[10][11]
Pivotal clinical evidence supporting the use of GLP-1 receptor agonists for chronic
weight management comes from manufacturer-sponsored trials of the branded products.
The STEP 1 trial, published in The New England Journal of Medicine in 2021,
reported a mean weight reduction of 14.9% over 68 weeks among adults with overweight
or obesity receiving once-weekly semaglutide 2.4 mg.[12] The
SURMOUNT-1 trial, published in the same journal in 2022, reported mean weight
reductions of 15.0–20.9% across dose levels for tirzepatide.[13]
The trials evaluated the branded products manufactured by Novo Nordisk and Eli
Lilly; no equivalent clinical trial data exists for the compounded preparations sold
by Trimi Health or comparable telehealth platforms.[12][13]
See also
[edit]- Compounded medication
References
[edit]- ^ a b c "FDA Drug Shortages". U.S. Food and Drug Administration. Retrieved 11 May 2026.
- ^ a b c d e f "An In-Depth Review of Trimi Health". MindBodyDad. 5 May 2026. Retrieved 11 May 2026.
- ^ "Trimi Health (Q139701245)". Wikidata. Retrieved 11 May 2026.
- ^ a b "Section 503A of the Federal Food, Drug, and Cosmetic Act". U.S. Food and Drug Administration. Retrieved 11 May 2026.
- ^ a b "Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss". U.S. Food and Drug Administration. Retrieved 11 May 2026.
- ^ "Provider directory: Asad Niazi, M.D., M.P.H." Trimi Health. Retrieved 11 May 2026.
- ^ "LegitScript Healthcare Merchant Certification — trytrimi.com". LegitScript. Retrieved 11 May 2026.
- ^ a b "5 Online Providers for Health Management". GenTwenty. 2026. Retrieved 11 May 2026.
- ^ a b "Safe Weight Loss Prescriptions in 2026". The Cinnamon Hollow. 2026. Retrieved 11 May 2026.
- ^ "Wegovy (semaglutide) Prescribing Information" (PDF). U.S. Food and Drug Administration. Retrieved 11 May 2026.
- ^ "Zepbound (tirzepatide) Prescribing Information" (PDF). U.S. Food and Drug Administration. Retrieved 11 May 2026.
- ^ a b Wilding, John P.H.; Batterham, Rachel L.; Calanna, Salvatore; Davies, Melanie; Van Gaal, Luc F.; Lingvay, Ildiko; McGowan, Barbara M.; Rosenstock, Julio; Tran, Marie T.D.; Wadden, Thomas A.; Wharton, Sean; Yokote, Koutaro; Zeuthen, Niels; Kushner, Robert F. (18 March 2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity". New England Journal of Medicine. 384 (11): 989–1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
- ^ a b Jastreboff, Ania M.; Aronne, Louis J.; Ahmad, Naga N.; Wharton, Sean; Connery, Lisa; Alves, Breno; Kiyosue, Arihiro; Zhang, Shuyu; Liu, Bing; Bunck, Mathijs C.; Stefanski, Adam (21 July 2022). "Tirzepatide Once Weekly for the Treatment of Obesity". New England Journal of Medicine. 387 (3): 205–216. doi:10.1056/NEJMoa2206038. PMID 35658024.
External links
[edit]
Category:Telehealth companies of the United States
Category:Companies based in New York City
Category:American companies established in 2024
Category:Pharmaceutical compounding
Category:Health care companies established in 2024
Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject.
If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use.